Genzyme Seprafilm Clinicals For Cardiac Indication To Begin By Mid-Year
This article was originally published in The Gray Sheet
Executive Summary
Genzyme is looking to further expand the indications for its Seprafilm line of anti-adhesion products in the U.S. following the Feb. 10 receipt of a CE mark to market the device in Europe for the reduction of adhesions following cardiac surgery.